mutational analysis reveals origin therapy-driven evolution recurrent glioma
tumor recurrence leading cause cancer mortality therapies recurrent disease may fail least part genomic alterations driving growth recurrences distinct initial tumor explore hypothesis sequenced exomes initial low-grade gliomas recurrent tumors resected patients % cases least half mutations initial tumor undetected recurrence including driver mutations tp53 atrx smarca4 braf suggests recurrent tumors often seeded cells derived initial tumor early stage evolution notably tumors patients treated chemotherapeutic drug temozolomide tmz followed alternative evolutionary path high-grade glioma recurrence tumors hypermutated harbored driver mutations rb retinoblastoma akt-mtor mammalian target rapamycin pathways bore signature tmz-induced mutagenesis
